OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Indexing: DOAJ-Directory of Open Access Journals.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2020  Archive: 2019 2018 2017

Special Issue

Mutant Melanoma

Submission Deadline: February 28, 2021 (Open) Submit Now

Guest Editor

Michela Roberto, MD

Assistant Professor, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University "La Sapienza", Rome, Italy;
Department of Medical-Surgical Sciences and Translation Medicine, Sant'Andrea Hospital, University "La Sapienza", Rome, Italy.

Website | E-Mail

Research Interests: oncology; clinical trials; cancer biomarkers; molecular oncology; gene expression; metastasis; colorectal cancer; chemotherapy.

About This Topic

Melanoma onset and progression are associated with a high variety of activating mutations (e.g BRAF, NRAS genes, most frequently, but also c-KIT and PTEN and others). Targeted therapies showed promising results over the past years, but it is known that most responses are temporary, and almost all of patients develop a tumor relapse within one year. Different drug-resistance mechanisms underlie the progression of disease and activation of both MAPK and PI3K/AKT/mTOR pathways. Therefore, we appreciate studies about possible gene pathways involved in mutant melanoma, clinical effects of several target inhibitors, describing properly the most prominent mechanisms of both intrinsic and acquired resistance, suggestive strategies for overcoming drug resistance and the most recent alternative combination therapies, as well as about new discovered drugs.

Newsletter

TOP